SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock and bond offerings to finance AI and data-center expansion are driving attention, with traders weighing dilution and debt concerns against managements view that the funding is part of a previously outlined investment plan. Bears criticize the timing and financial risk, while bulls see the capital raise as necessary to support growth.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders focused on the fixed share-exchange ratio and the long wait for the deal to close. Many LITE holders object to the terms and worry its value will track Marvells share price, helping explain the selloff despite the announced premium; others see strategic value in combining optics and AI-data-center connectivity businesses.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum is driving discussion, as the deal aims to combine Marvells connectivity chips with Lumentums optical technology for AI data centers. Traders are divided: some see strategic value in expanding Marvells optics business, while others worry about shareholder dilution, the deals cost and long path to completion, contributing to selling pressure.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluences CEO, CFO and chief customer success officer are leaving, with interim leaders appointed and permanent searches underway. Traders are split between viewing the shake-up as a chance to reset management and doubting it will fix the companys manufacturing and execution problems; some also speculate about short-squeeze potential.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Discussion centers on POETs photonics positioning amid Foxconn Tech Day visibility and Marvells Lumentum deal, with traders debating whether industry consolidation validates demand and creates opportunities for POET or intensifies competition. The optimism is tempered by concerns that the Foxconn display is not proof of production orders, with many awaiting shipment and revenue updates at the upcoming earnings report.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has raised concerns about pressure on Precigens PAPZIMEOS and prompted a sharp selloff. Traders are divided over the rivals potential treatment advantages versus PAPZIMEOSs commercial head start and established payer access, with upcoming earnings seen as a key test of launch momentum.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsomes Q3 results beat expectations, with strong growth in its commercial portfolio, particularly Auvelity, prompting bullish reactions about the companys path toward cash-flow positivity. The shares decline despite the report has frustrated investors, while others point to rising expenses and the lack of quantified guidance on profitability as reasons for caution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of Q3 results has traders focused on BRIUMVIs sales momentum, bullish options activity and the possibility of a short squeeze. Buyout speculation is also prominent, but remains unconfirmed.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus drew attention after reporting quarterly results above expectations and raising its full-year revenue outlook, with growth in oncology testing and Data & Applications supporting the business story. Traders were broadly upbeat about the beat and higher guidance, but some questioned how much the narrower loss reflected underlying improvement, while the shares decline prompted sell the news and volatility concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas preliminary warning that DefenCath reimbursement could decline through 2027 has driven sharp selling, raising concerns about CorMedixs pricing, revenue and customer uptake. Traders disagree on the implications: some view DaVitas estimates as uncertain and point to continued adoption and CMS reimbursement, while others worry about lower economics and competition from ClearGuard.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
